REWIND gives Trulicity a cardiovascular indication

Results from REWIND, a double-blind randomized placebo-controlled trial of the weekly GLP-1 drug dulaglutide (sold as Trulicity), were published in The Lancet. Among 9,901 people with type 2 diabetes followed for a median of 5.4 years, dulaglutide 1.5 mg reduced major adverse cardiovascular events compared with placebo ^[1].

What the trial found

The main outcome was a composite of major adverse cardiovascular events, often called MACE. It occurred in 12.0% of people assigned to dulaglutide versus 13.4% of those assigned to placebo, a hazard ratio of 0.88 ^[1]. In plain terms, that is a 12% lower relative risk and a difference of about 1.4 percentage points in absolute terms across more than five years of follow-up.

Most of that benefit came from one component of the composite: nonfatal stroke, which fell by 24% ^[1]. That pattern sets REWIND apart from several other diabetes outcome trials, where reductions in heart attack or cardiovascular death drove the result.

The other notable feature is who was enrolled. Most participants did not have established cardiovascular disease when they entered the trial ^[1]. Earlier GLP-1 outcome trials generally recruited people who had already had a heart attack, a stroke, or documented artery disease. REWIND tested a broader group that included people with cardiovascular risk factors but no prior event, and the follow-up period — a median of 5.4 years — was longer than in most comparable studies ^[1].

Where this fits among GLP-1 drugs

Dulaglutide is a once-weekly GLP-1 receptor agonist, the same drug class as semaglutide (Ozempic, Wegovy, Rybelsus) and the related dual agonist tirzepatide (Mounjaro, Zepbound). It is not semaglutide, and results from one molecule in the class do not automatically transfer to another. Each product's labeling reflects its own trials.

The development here is framed as a cardiovascular indication for Trulicity, meaning the trial data support adding heart-related language to the product's prescribing information. The Lancet publication is the underlying evidence ^[1]. The specific wording of any regulatory decision, the date it took effect, and exactly which patient population it covers are not described in the source available here, so those details are not yet established from this reporting.

Several other things are also not covered in the source text provided: rates of side effects such as nausea or vomiting, discontinuation rates, effects on body weight or A1C, kidney outcomes, and how many participants had prior cardiovascular disease as a precise percentage. Those figures appear in the full publication but are not reproducible here without guessing.

Why it matters for patients

For adults with type 2 diabetes, a cardiovascular claim on a label changes the conversation from blood sugar alone to longer-term risk. It gives prescribers a documented reason to consider a drug in this class for someone whose main concern is preventing a heart attack or stroke, not just lowering A1C. Insurers and formulary committees also weigh label indications when deciding coverage tiers and prior-authorization rules.

The primary-prevention angle matters too. Because most REWIND participants had not already had a cardiovascular event ^[1], the findings speak to a larger group of people with diabetes than trials limited to those with known heart disease.

It is worth keeping the size of the effect in view. Over a median of 5.4 years, the difference between the two groups was 12.0% versus 13.4% ^[1]. That is a real but modest absolute reduction, and it comes from a trial in people with type 2 diabetes — not from a study of weight loss in people without diabetes.

None of this says anything about which drug fits any individual, what dose is appropriate, or whether switching makes sense. Those are decisions for a clinician who knows a person's history.

What happens next

The REWIND publication in The Lancet is dated to this development on June 9, 2019 ^[1]. Any follow-on analyses — such as subgroup results by baseline cardiovascular status, kidney endpoints, or cost-effectiveness reviews — would appear separately and are not part of the source here.